Plus Therapeutics (PSTV) Depreciation & Amortization (CF) (2010 - 2026)
Plus Therapeutics (PSTV) reported Depreciation & Amortization (CF) of $96000.0 for Q1 2026, down 34.25% year-over-year from $146000.0 in Q1 2025, and down 33.79% quarter-over-quarter from $145000.0 in Q4 2025.
Plus Therapeutics (PSTV) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $96000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $96000.0, down 34.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $395000.0 (down 54.23% YoY), and the FY2025 annual result was $445000.0, down 48.97% from the prior year.
- Depreciation & Amortization (CF) retreated to $96000.0 in Q1 2026 per PSTV's latest filing, from $145000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $348000.0 in Q4 2024 and troughed at $77000.0 in Q2 2025.
- A 5-year average of $156470.6 and a median of $155000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 130.46% in 2024, then plunged 61.31% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $159000.0 in 2022, then fell by 5.03% to $151000.0 in 2023, then surged by 130.46% to $348000.0 in 2024, then slumped by 58.33% to $145000.0 in 2025, then sank by 33.79% to $96000.0 in 2026.
- Business Quant data shows PSTV's Depreciation & Amortization (CF) at $96000.0 in Q1 2026, $145000.0 in Q4 2025, and $77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Plus Therapeutics | 33.89 Mn | 18.78 Mn | - | 96,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96,000.00 |
| Mar 31, 2026 | 96,000.00 |
| Dec 31, 2025 | 145,000.00 |
| Dec 31, 2025 | 145,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Sep 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Dec 31, 2024 | 348,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Mar 31, 2024 | 155,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Dec 31, 2023 | 151,000.00 |